BioNTech says its Phase 3 trial will test pumitamig with Gilead’s sacituzumab govitecan in triple-negative breast cancer.
BioNTech is advancing a Phase 3 trial of pumitamig combined with Gilead Sciences’ sacituzumab govitecan. The supplied information does not include enrollment details, a timeline, or trial results. For Gilead investors, this is a clinical-development update, not evidence of a treatment outcome.
Investor takeaway: The combination is moving into Phase 3 testing. The available details don’t establish the trial’s results, timing, or potential commercial impact for Gilead.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$194.07B
Div. yield
2.10%
Div. / share
$3.22
52W high
$160.51
52W low
$111.27
1W change
+0.02%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 22, 2026
Wall Street analysts forecast GILD stock price to rise 415.6% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$160.15
+415.6% Upside
Previously C$159.85 on Oct 19, 2026
Current Price
C$31.06
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
24.5%
Annualized
90-Day Vol
27.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$183.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$162.99 | C$149.80 – C$177.34 |
| 60 trading days | C$172.98 | C$153.52 – C$194.92 |
| 90 trading days | C$183.59 | C$158.62 – C$212.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Gilead closed at US$154.86
Gilead’s supplied quote data show a 1.88% decline for the day and a 28.56% gain year to date. Latest volume was 5,952 shares, compared with a 20-day average of 5,641,657. The data don’t show that the trial announcement caused the share-price move.
Bull case
The combination is advancing to Phase 3 testing for triple-negative breast cancer, according to the supplied headline.
Bear case
The supplied information includes no trial results, enrollment details, schedule, or expected financial contribution. The announcement alone doesn’t show whether the combination will benefit patients or Gilead.
BioNTech advances the combination into Phase 3
Advertisement
The October 22 headline says BioNTech is advancing a Phase 3 trial of pumitamig with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan for triple-negative breast cancer. The supplied information doesn’t describe the trial design, planned enrollment, expected start or completion dates, or any results. This is a clinical-development update, not an approval announcement.
Gilead shares closed at US$154.86
Gilead’s supplied last close was US$154.86, down 1.88% for the day. The stock was up 0.02% over one week, 2.00% over one month, and 28.56% year to date. Latest volume was 5,952 shares, compared with a 20-day average of 5,641,657 shares. The supplied facts report volume at 1.10 times the average, though the figures shown don’t support that ratio. They also don’t show that the trial announcement drove the share-price move. See the Gilead stock page for the supplied quote information.
Trial details and results remain unknown
Further details about the Phase 3 trial and, eventually, its results will help clarify the significance of this update. The supplied headline gives no timeline or upcoming milestones, so there’s no specific date or readout to report. It also doesn’t say what commercial contribution the combination could make to Gilead. The Gilead stock page has company and share information, but the supplied facts don’t support a financial forecast tied to this trial.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
